ELOXX PHARMACEUTICALS, INC. Operating Expenses
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Operating Expenses of $4.45 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $4.45M, a 181.29% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $3.79M, a 210.56% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-06-30 was $1.58M.
- ELOXX PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-03-31 was $1.22M.
- ELOXX PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $34.42M, a 47.86% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. operating expenses for fiscal 2021 was $66.02M, a 97.33% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. operating expenses for fiscal 2020 was $33.45M, a 33.82% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. operating expenses for fiscal 2019 was $50.55M, a 6.29% increase from fiscal 2018.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.45M S-1 · filed 2026-09-11 | $8.25M S-1 · filed 2026-09-11 | ||
| 2026-03-31 | $3.79M S-1/A · filed 2026-06-04 | |||
| 2025-12-31 | $6.44M S-1 · filed 2026-09-11 | |||
| 2025-06-30 | $1.58M S-1 · filed 2026-09-11 | $2.80M S-1 · filed 2026-09-11 | ||
| 2025-03-31 | $1.22M S-1/A · filed 2026-06-04 | |||
| 2024-12-31 | $8.83M S-1 · filed 2026-09-11 | |||
| 2023-12-31 | $4.03M derived: S-1 12 month − 10-Q 9 month · filed 2026-09-11 | $7.67M derived: sum of 2 quarters · filed 2026-09-11 | $11.80M derived: sum of 3 quarters · filed 2026-09-11 | $17.29M S-1 · filed 2026-09-11 |
| 2023-09-30 | $3.64M 10-Q · filed 2023-11-13 | $7.78M derived: sum of 2 quarters · filed 2023-11-13 | $13.26M 10-Q · filed 2023-11-13 | $19.29M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $4.14M 10-Q · filed 2023-08-11 | $9.62M 10-Q · filed 2023-08-11 | $15.65M derived: sum of 3 quarters · filed 2023-08-11 | $22.79M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $5.48M 10-Q · filed 2023-05-12 | $11.51M derived: sum of 2 quarters · filed 2023-05-12 | $18.65M derived: sum of 3 quarters · filed 2023-11-13 | $28.95M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $13.17M derived: sum of 2 quarters · filed 2023-11-13 | $23.47M derived: sum of 3 quarters · filed 2023-11-13 | $34.42M 10-K · filed 2023-03-31 |
| 2022-09-30 | $7.14M 10-Q · filed 2023-11-13 | $17.44M derived: sum of 2 quarters · filed 2023-11-13 | $28.39M 10-Q · filed 2023-11-13 | $40.02M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $10.30M 10-Q · filed 2023-08-11 | $21.25M 10-Q · filed 2023-08-11 | $32.88M derived: sum of 3 quarters · filed 2023-08-11 | $43.12M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $10.95M 10-Q · filed 2023-05-12 | $22.58M derived: sum of 2 quarters · filed 2023-05-12 | $32.83M derived: sum of 3 quarters · filed 2023-05-12 | $68.56M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $21.88M derived: sum of 2 quarters · filed 2023-03-31 | $57.60M derived: sum of 3 quarters · filed 2023-03-31 | $66.02M 10-K · filed 2023-03-31 |
| 2021-09-30 | $10.24M 10-Q · filed 2022-11-10 | $45.97M derived: sum of 2 quarters · filed 2022-11-10 | $54.39M 10-Q · filed 2022-11-10 | $60.19M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $35.73M 10-Q · filed 2022-08-12 | $44.14M 10-Q · filed 2022-08-12 | $49.95M derived: sum of 3 quarters · filed 2022-08-12 | $56.24M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $8.41M 10-Q · filed 2022-05-06 | $14.22M derived: sum of 2 quarters · filed 2022-05-06 | $20.52M derived: sum of 3 quarters · filed 2022-05-06 | $28.10M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $12.10M derived: sum of 2 quarters · filed 2022-03-30 | $19.69M derived: sum of 3 quarters · filed 2022-03-30 | $33.45M 10-K · filed 2022-03-30 |
| 2020-09-30 | $6.30M 10-Q · filed 2021-11-08 | $13.88M derived: sum of 2 quarters · filed 2021-11-08 | $27.65M 10-Q · filed 2021-11-08 | $39.14M derived: sum of 4 quarters · filed 2022-03-30 |
| 2020-06-30 | $7.59M 10-Q · filed 2021-08-16 | $21.35M 10-Q · filed 2021-08-16 | $32.84M derived: sum of 3 quarters · filed 2022-03-30 | $45.62M derived: sum of 4 quarters · filed 2022-03-30 |
| 2020-03-31 | $13.77M 10-Q · filed 2021-05-07 | $25.25M derived: sum of 2 quarters · filed 2022-03-30 | $38.03M derived: sum of 3 quarters · filed 2022-03-30 | $52.34M derived: sum of 4 quarters · filed 2022-03-30 |
| 2019-12-31 | $11.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $24.27M derived: sum of 2 quarters · filed 2022-03-30 | $38.58M derived: sum of 3 quarters · filed 2022-03-30 | $50.55M 10-K · filed 2022-03-30 |
| 2019-09-30 | $12.78M 10-Q · filed 2020-11-06 | $27.09M derived: sum of 2 quarters · filed 2020-11-06 | $39.07M 10-Q · filed 2020-11-06 | $53.18M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $14.31M 10-Q · filed 2020-08-07 | $26.29M 10-Q · filed 2020-08-07 | $40.40M derived: sum of 3 quarters · filed 2021-03-12 | $51.76M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $11.98M 10-Q · filed 2020-05-08 | $26.09M derived: sum of 2 quarters · filed 2021-03-12 | $37.45M derived: sum of 3 quarters · filed 2021-03-12 | $50.99M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $14.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $25.47M derived: sum of 2 quarters · filed 2021-03-12 | $39.02M derived: sum of 3 quarters · filed 2021-03-12 | $47.56M 10-K · filed 2021-03-12 |
| 2018-09-30 | $11.36M 10-Q · filed 2019-11-06 | $24.90M derived: sum of 2 quarters · filed 2019-11-06 | $33.45M 10-Q · filed 2019-11-06 | $44.03M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | $13.54M 10-Q · filed 2019-08-07 | $22.09M 10-Q · filed 2019-08-07 | $32.67M derived: sum of 3 quarters · filed 2020-03-06 | $36.67M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | $8.55M 10-Q · filed 2019-05-09 | $19.13M derived: sum of 2 quarters · filed 2020-03-06 | $23.13M derived: sum of 3 quarters · filed 2020-03-06 | $26.31M derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $10.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $14.58M derived: sum of 2 quarters · filed 2020-03-06 | $17.76M derived: sum of 3 quarters · filed 2020-03-06 | $20.39M 10-K · filed 2020-03-06 |
| 2017-09-30 | $4.00M 10-Q · filed 2018-11-08 | $7.18M derived: sum of 2 quarters · filed 2018-11-08 | $9.81M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $3.18M 10-Q · filed 2018-08-10 | $5.81M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $2.63M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $9.84M 10-K · filed 2019-03-14 | |||
| 2015-12-31 | $6.28M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |